tirzepatide shortage fda US judge sides with FDA's removal of Lilly's weight loss drug from list Important Announcement FDA Update on

The increasing prevalence of obesity and its associated health risks created a significant unmet need for effective weight loss treatments

& Levine, S

A vial near its expiration may contain less active tirzepatide per milliliter than a fresh vial, effectively lowering the true concentration below what the label states

Emerging evidence suggests that this variability is largely attributable to genetic factors, particularly single nucleotide polymorphisms (SNPs) in genes encoding its primary pharmacological targetsGLP1R and GIPRas well as in genes regulating insulin secretion, adiposity, and appetite control [10]

The pharmacy doing the actual compounding determines the quality of what ends up in your vial